http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature.

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/MONDO_0005689 MONDO_0005689

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/DRUGBANK:DB00490 DRUGBANK:DB00490

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/has_population_context has_population_context

http://purl.org/np/RA5NQSrZvE...#context context

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/publications publications

https://pubmed.ncbi.nlm.nih.gov/32227801 pubmed.ncbi.nlm.nih.gov/32227801

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

0000-0002-7641-6446

2021-08-24T19:10:10.436Z

http://purl.org/np/RA5NQSrZvE... RA5NQSrZvE

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/OffLabelIndication OffLabelIndication

0000-0002-7641-6446

2021-08-24T19:10:10.436Z